Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Vita Genomics, Inc.

Lawrence Shih-Hsin Wu1, Chun-Lin Su, Ellson Chen

  • 1Vita Genomics, Inc., 7Fl. No.6, Sec.1, Jungshing Rd., Wugu Shiang, Taipei, 248 Taiwan. ellson.chen@vitagenomics.com

Pharmacogenomics
|June 15, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pediatric post-acute sequelae of SARS-CoV-2 infection in Taiwan: Insights from the DISCOVER cohort.

Pediatrics and neonatology·2026
Same author

Echocardiographic Evaluation in Children with Post-Acute Sequelae of SARS-CoV-2 Infection Using Deep Learning.

Journal of imaging informatics in medicine·2026
Same author

The impact of COVID-19 on the incidence of allergic diseases in the pediatric population: A retrospective cohort study from TriNetX United States collaborative network.

Asia Pacific allergy·2025
Same author

Distinct regional allergen sensitization patterns in pediatric populations: A comparative latent class analysis of multiple antigen simultaneous test-derived sensitization profiles in Japan and Taiwan.

Asia Pacific allergy·2025
Same author

Anti-nucleocapsid antibody levels reflect post-acute sequelae of COVID-19 symptom burden in children.

Journal of infection and public health·2025
Same author

Maternal vitamin D and genetic variants determine cord blood vitamin D levels in newborn.

Pediatric research·2025
Same journal

Closely similar tacrolimus morning troughs and graft function across the recipients' common <i>ABCB1</i> polymorphisms (<i>c.2677G>T/A</i>, <i>c.1236C>T</i>, <i>c.3435C>T</i>) early after renal transplantation.

Pharmacogenomics·2026
Same journal

Pharmacogenomics for stratified antidepressant treatment in major depressive disorder: evidence, limits and a roadmap for clinical use.

Pharmacogenomics·2026
Same journal

Guidance from an informed public on collecting and sharing PGx test results for major depressive disorder: "It's no different from your blood type".

Pharmacogenomics·2026
Same journal

Optimizing pharmacogenomics workflows: a qualitative evaluation of clinical service delivery models.

Pharmacogenomics·2026
Same journal

Combinations of single gene predictors with AI-driven polygenic precision therapies in cardiovascular diseases.

Pharmacogenomics·2026
Same journal

Practical guide to implementing pre-emptive pharmacogenetic screening in routine pediatric oncology care.

Pharmacogenomics·2026
See all related articles

Vita Genomics is launching a drug rescue program using pharmacogenomics to identify patient subsets likely to respond to previously failed drugs. This approach aims to improve drug efficacy and safety through biomarker-driven patient selection.

Area of Science:

  • Biotechnology
  • Biopharmaceuticals
  • Genomics
  • Pharmacogenomics

Background:

  • Vita Genomics, Inc. is a biotechnology company in Taiwan and China.
  • The company specializes in genomics and pharmacogenomics research, in vitro diagnostics, and contract research services.

Purpose of the Study:

  • To initiate a drug rescue program for drugs that failed due to low efficacy.
  • To apply pharmacogenomics approaches with biomarkers for patient stratification.
  • To improve drug development by identifying patient subsets with better response or fewer adverse events.

Main Methods:

  • Utilizing pharmacogenomics research.
  • Developing in vitro diagnostic products.
  • Implementing biomarker screening for patient subsets.

Related Experiment Videos

  • Conducting specialty contract research services.

    • Main Results:

    • Not applicable for this program description.

    Conclusions:

    • Vita Genomics aims to be a leader in the Asia-Pacific genomics and biopharmaceutical market.
    • The company seeks to revolutionize drug development through pharmacogenomic solutions and advanced diagnostics.
    • The drug rescue program is expected to enhance the success rate of previously failed drugs.